Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates

Gene Therapy volume 22, pages 116–126 (2015)Cite this article

Subjects

Abstract

Gene delivery vectors based on adeno-associated viruses (AAV) have exhibited promise in both preclinical disease models and human clinical trials for numerous disease targets, including the retinal degenerative disorders Leber’s congenital amaurosis and choroideremia. One general challenge for AAV is that preexisting immunity, as well as subsequent development of immunity following vector administration, can severely inhibit systemic AAV vector gene delivery. However, the role of neutralizing antibodies (NABs) in AAV transduction of tissues considered to be immune privileged, such as the eye, is unclear in large animals. Intravitreal AAV administration allows for broad retinal delivery, but is more susceptible to interactions with the immune system than subretinal administration. To assess the effects of systemic anti-AAV antibody levels on intravitreal gene delivery, we quantified the anti-AAV antibodies present in sera from non-human primates before and after intravitreal injections with various AAV capsids. Analysis showed that intravitreal administration resulted in an increase in anti-AAV antibodies regardless of the capsid serotype, transgene or dosage of virus injected. For monkeys injected with wild-type AAV2 and/or an AAV2 mutant, the variable that most significantly affected the production of anti-AAV2 antibodies was the amount of virus delivered. In addition, post-injection antibody titers were highest against the serotype administered, but the antibodies were also cross-reactive against other AAV serotypes. Furthermore, NAB levels in serum correlated with those in vitreal fluid, demonstrating both that this route of administration exposes AAV capsid epitopes to the adaptive immune system and that serum measurements are predictive of vitreous fluid NAB titers. Moreover, the presence of preexisting NAB titers in the serum of monkeys correlated strongly (R=0.76) with weak, decaying or no transgene expression following intravitreal administration of AAV. Investigating anti-AAV antibody development will aid in understanding the interactions between gene therapy vectors and the immune system during ocular administration and can form a basis for future clinical studies applying intravitreal gene delivery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Knipe DM, Howley PM . Fields’ Virology. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.

    Google Scholar 

  2. Sonntag F, Schmidt K, Kleinschmidt JA . A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 2010; 107: 10220–10225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sonntag F, Köther K, Schmidt K, Weghofer M, Raupp C, Nieto K et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 2011; 85: 12686–12697.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schaffer D V, Koerber JT, Lim K . Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 2008; 10: 169–194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wu Z, Asokan A, Samulski RJ . Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316–327.

    Article  CAS  PubMed  Google Scholar 

  6. Flotte TR . Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004; 11: 805–810.

    Article  CAS  PubMed  Google Scholar 

  7. Gene Therapy Clinical Trials Worldwide. J. Gene Med. 2014. http://www.abedia.com/wiley/ (accessed 18 March 2014).

  8. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan A V, Schwartz SB, Wang L et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979–990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cideciyan A V, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009; 20: 999–1004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2231–2239.

    Article  CAS  PubMed  Google Scholar 

  11. Maguire A, Simonelli F . Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008; 358: 2240–2248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Maguire AM, High K a, Auricchio A, Wright JF, Pierce E a, Testa F et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597–1605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bennett J, Ashtari M, Wellman J, Marshall K a, Cyckowski LL, Chung DC et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra15.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Jacobson SG, Cideciyan A V, Ratnakaram R, Heon E, Schwartz SB, Roman AJ et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012; 130: 9–24.

    Article  CAS  PubMed  Google Scholar 

  15. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014; 6736: 2117–2120.

    Google Scholar 

  16. Koerber JT, Klimczak R, Jang J-H, Dalkara D, Flannery JG, Schaffer DV . Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009; 17: 2088–2095.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463–471.

    Article  CAS  PubMed  Google Scholar 

  18. Aleman TS, Cideciyan A V, Sumaroka A, Windsor EAM, Herrera W, White DA et al. Retinal laminar architecture in human retinitis pigmentosa caused by Rhodopsin gene mutations. Invest Ophthalmol Vis Sci 2008; 49: 1580–1590.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jacobson SG, Aleman TS, Cideciyan A V, Roman AJ, Sumaroka A, Windsor EAM et al. Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 2009; 50: 2368–2375.

    Article  PubMed  Google Scholar 

  20. Jacobson SG, Aleman TS, Sumaroka A, Cideciyan A V, Roman AJ, Windsor EAM et al. Disease boundaries in the retina of patients with Usher syndrome caused by MYO7A gene mutations. Invest Ophthalmol Vis Sci 2009; 50: 1886–1894.

    Article  PubMed  Google Scholar 

  21. Nakazawa T, Matsubara A, Noda K, Hisatomi T, She H, Skondra D et al. Characterization of cytokine responses to retinal detachment in rats. Mol Vis 2006; 12: 867–878.

    CAS  PubMed  Google Scholar 

  22. Nakazawa T, Takeda M, Lewis GP, Cho K-S, Jiao J, Wilhelmsson U et al. Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci 2007; 48: 2760–2768.

    Article  PubMed  Google Scholar 

  23. Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, Sieving PA et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009; 16: 916–926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV . A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One 2009; 4: e7467.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013; 5: 189ra76.

    Article  PubMed  Google Scholar 

  26. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342–347.

    Article  CAS  PubMed  Google Scholar 

  27. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28: 2303–2304.

    Article  CAS  PubMed  Google Scholar 

  28. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704–712.

    Article  CAS  PubMed  Google Scholar 

  29. Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther 2010; 18: 126–134.

    Article  CAS  PubMed  Google Scholar 

  30. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector–mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357–2365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171–181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier M-C, Bessis N . Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J Clin Immunol 2004; 24: 162–169.

    Article  CAS  PubMed  Google Scholar 

  33. Boissier M-C, Lemeiter D, Clavel C, Valvason C, Laroche L, Begue T et al. Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype. Hum Gene Ther 2007; 18: 525–535.

    Article  CAS  PubMed  Google Scholar 

  34. Samaranch L, Salegio E a, San Sebastian W, Kells AP, Bringas JR, Forsayeth J et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 2013; 24: 526–532.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sanftner LM, Suzuki BM, Doroudchi MM, Feng L, McClelland A, Forsayeth JR et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 2004; 9: 403–409.

    Article  CAS  PubMed  Google Scholar 

  36. Li Q, Miller R, Han P-Y, Pang J, Dinculescu A, Chiodo V et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008; 14: 1760–1769.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Amado D, Mingozzi F, Hui D, Bennicelli JL, Wei Z, Chen Y et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med 2010; 2: 21ra16.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mingozzi F, High KA . Immune responses to AAV in clinical trials. Curr Gene Ther 2011; 11: 321–330.

    Article  CAS  PubMed  Google Scholar 

  39. Halbert CL, Standaert TA, Wilson CB, Miller AD . Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795–9805.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108: 3321–3328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V . Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998; 9: 477–485.

    Article  CAS  PubMed  Google Scholar 

  42. McPhee SWJ, Janson CG, Li C, Samulski RJ, Camp a S, Francis J et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006; 8: 577–588.

    Article  CAS  PubMed  Google Scholar 

  43. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304–313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Yin L, Masella B, Dalkara D, Zhang J, Flannery JG, Schaffer DV et al. Imaging light responses of foveal ganglion cells in the living macaque eye. J Neurosci 2014; 34: 6596–6605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105: 7827–7832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Martin KRG, Klein RL, Quigley HA . Gene delivery to the eye using adeno-associated viral vectors. Methods 2002; 28: 267–275.

    Article  CAS  PubMed  Google Scholar 

  48. Hoffman LM, Maguire AM, Bennett J . Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci 1997; 38: 2224–2233.

    CAS  PubMed  Google Scholar 

  49. Benson WE, Brown GC, Tasman W, McNamara JA . Complications of vitrectomy for non-clearing vitreous hemorrhage in diabetic patients. Ophthalmic Surg 1988; 19: 862–864.

    CAS  PubMed  Google Scholar 

  50. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD . Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74: 1524–1532.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Peden CS, Burger C, Muzyczka N, Mandel RJ . Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344–6359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM . Gene Therapy Vectors Based on Adeno-Associated Virus Type 1. J Virol 1999; 73: 3994–4003.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Gao G-P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM . Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA . Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther 2012; 23: 733–741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381–6388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bantel-Schaal U, Delius H, Schmidt R, zur Hausen H . Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol 1999; 73: 939–947.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM . Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008; 19: 663–669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD . Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71: 5932–5941.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011; 22: 1389–1401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Gaudet D, de Wal J, Tremblay K, Déry S, van Deventer S, Freidig A et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010; 11: 55–60.

    Article  CAS  PubMed  Google Scholar 

  61. Carpentier AC, Frisch F, Labbé SM, Gagnon R, de Wal J, Greentree S et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012; 97: 1635–1644.

    Article  CAS  PubMed  Google Scholar 

  62. Willett K, Bennett J . Immunology of AAV-Mediated Gene Transfer in the Eye. Front Immunol 2013; 4: 261.

    Article  PubMed  PubMed Central  Google Scholar 

  63. De Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud M-C et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004; 34: 3702–3712.

    Article  CAS  PubMed  Google Scholar 

  64. Van der Voet J, Liem A, Otto A, Kijlstra A . Intraocular antibody synthesis during experimental uveitis. Invest Ophthalmol Vis Sci 1989; 30: 316–322.

    CAS  PubMed  Google Scholar 

  65. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003; 10: 2139–2147.

    Article  CAS  PubMed  Google Scholar 

  66. Kolstad KD, Dalkara D, Guerin K, Visel M, Hoffmann N, Schaffer DV et al. Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum Gene Ther 2010; 21: 571–578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Vacca O, Darche M, Schaffer D V, Flannery JG, Sahel J-A, Rendon A et al. AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers. Glia 2014; 62: 468–476.

    Article  PubMed  Google Scholar 

  68. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV . Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24: 198–204.

    Article  CAS  PubMed  Google Scholar 

  69. Koerber JT, Jang J-H, Schaffer DV . DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008; 16: 1703–1709.

    Article  CAS  PubMed  Google Scholar 

  70. Bartel MA, Hwang B-Y, Stone D, Koerber JT, Couto L, Mingozzi F et al. Directed evolution of aav for enhanced evasion of human neutralizing antibodies. American Society of Gene and Cell Therapy’s 15th Annual Meeting 2012: Philadelphia, PA, USA S140.

    Google Scholar 

  71. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med 2006; 8: 155–162.

    Article  CAS  PubMed  Google Scholar 

  72. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82: 5887–5911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 2006; 80: 821–834.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761–1766.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Wobus CE, Hügle-Dörr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA . Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 2000; 74: 9281–9293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013; 5: 194ra92.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Excoffon KJD, Koerber JT, Dickey DD, Murtha M, Keshavjee S, Kaspar BK et al. Directed evolution of adeno-associated virus to an infectious respiratory virus. Proc Natl Acad Sci USA 2009; 106: 3865–3870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Strazzeri JM, Hunter JJ, Masella BD, Yin L, Fischer WS, DiLoreto DA et al. Focal damage to macaque photoreceptors produces persistent visual loss. Exp Eye Res 2014; 119: 88–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, USA

    M A Kotterman & D V Schaffer

  2. Flaum Eye Institute and Center for Visual Science, University of Rochester, Rochester, NY, USA

    L Yin, J M Strazzeri & W H Merigan

  3. The Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA

    J G Flannery & D V Schaffer

  4. Department of Molecular and Cellular Biology, University of California, Berkeley, CA, USA

    J G Flannery & D V Schaffer

  5. Department of Bioengineering, University of California, Berkeley, CA, USA

    D V Schaffer

  6. 4D Molecular Therapeutics, San Francisco, CA, USA

    M A Kotterman & D V Schaffer

Authors
  1. M A Kotterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J M Strazzeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J G Flannery
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W H Merigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D V Schaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D V Schaffer.

Ethics declarations

Competing interests

MAK, JGF and DVS are inventors on patents related to engineering of adeno-associated viruses, and MAK and DVS are associated with a company (4D Molecular Therapeutics) involved in AAV vector engineering.

Additional information

Supplementary Information accompanies this paper on Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotterman, M., Yin, L., Strazzeri, J. et al. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther 22, 116–126 (2015). https://doi.org/10.1038/gt.2014.115

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2014.115

This article is cited by

Search

Advanced search

Quick links